Stockscreener 앱 받기
62.14
1.16%
0.71
Travere Therapeutics Inc 주식(TVTX)의 최신 뉴스
S&CO Inc. Makes New Investment in Travere Therapeutics, Inc. $TVTX - MarketBeat
TVTX Stock Slides 6% On Everest Deal, Erases Some Losses As Analyst Sees 49% Upside - Stocktwits
TVTX Stock On Track To Hit Near 20-Year Highs After Filspari Becomes The Only Approved FSGS Treatment - Stocktwits
Travere Therapeutics (TVTX) sees Armistice Capital report 1.67% ownership in 13G/A - Stock Titan
Bank of America Corp DE Trims Position in Travere Therapeutics, Inc. $TVTX - MarketBeat
(TVTX) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Travere Therapeutics, Inc. Stock 12‑Month Price Target Raised to $74.62, Implies 20% Upside - TradingView
Travere Therapeutics (TVTX) Is Up 7.5% After Strong Q2 Revenue But Wider Net LossHas The Bull Case Changed? - simplywall.st
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule - TradingView
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Bank of America Corp (TVTX) discloses 5.8% beneficial stake in Travere Therapeutics - Stock Titan
What is HC Wainwright's Estimate for TVTX Q3 Earnings? - MarketBeat
Travere Therapeutics, Inc. $TVTX Shares Bought by Quantinno Capital Management LP - MarketBeat
Travere Therapeutics (TVTX) Q2 2026 Earnings Call Transcript - AOL.com
Travere Therapeutics Inc (TVTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Travere Therapeutics Wins Much-Awaited Approval For Drug In Rare Kidney Disease - Stocktwits
TVTX Maintained by Evercore ISI Group -- Price Target Raised to $78 - GuruFocus
Wall Street Analysts Are Neutral on Top Healthcare Picks - The Globe and Mail
California State Teachers Retirement System Increases Stock Holdings in Travere Therapeutics, Inc. $TVTX - MarketBeat
Assenagon Asset Management S.A. Boosts Stock Holdings in Travere Therapeutics, Inc. $TVTX - MarketBeat
Hennion & Walsh Asset Management Inc. Raises Holdings in Travere Therapeutics, Inc. $TVTX - MarketBeat
Travere Therapeutics Reports First Quarter 2026 Financial Results - The National Law Review
Travere Therapeutics, Inc. (TVTX) Stock Price, News, Quote & History - Yahoo! Finance Canada
State Street Corporation (TVTX) discloses 4.6% beneficial stake in Travere - Stock Titan
Wedbush Sticks to Their Buy Rating for Travere Therapeutics (TVTX) - The Globe and Mail
Travere Therapeutics (TVTX) Gets a Buy from Wells Fargo - The Globe and Mail
Travere Therapeutics Inc (TVTX) Stock News Today - TradingKey
Why Travere Therapeutics (TVTX) Is Up 9.0% After FILSPARI-Driven Q2 Revenue Jump And Wider Loss - Yahoo Finance
TVTX, LGND Stocks In Spotlight Ahead Of Monday’s FDA Call On Kidney Drug Filspari - Stocktwits
Travere Therapeutics (TVTX) On Q2 Results And FILSPARI Hopes As Fair Value Stays In View - Yahoo Finance Singapore
TVTX Maintained by Canaccord Genuity -- Price Target Raised to $70 - GuruFocus
Travere Therapeutics, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:TVTX) 2026-08-06 - Seeking Alpha
Travere Therapeutics Is Maintained at Buy by Canaccord Genuity - Moomoo
Travere Therapeutics (TVTX) Stock Rallies Over 13% After Hours: Here's What Is Going On - webull.com
TVTX Maintained by Wedbush -- Price Target Raised to $75 - GuruFocus
FMR LLC (TVTX) discloses 7.1M Travere Therapeutics shares under amended 13G - stocktitan.net
Travere Therapeutics, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Travere Therapeutics Q2 Earnings: Why I'm Downgrading To Hold (Again) (NASDAQ:TVTX) - Seeking Alpha
Can Travere Therapeutics (TVTX) Be A Bargain After Its Q2 Surge? - Yahoo Finance
Empowered Funds LLC Increases Holdings in Travere Therapeutics, Inc. $TVTX - MarketBeat
Travere Therapeutics, Inc. $TVTX Shares Acquired by Sei Investments Co. - MarketBeat
TRAVERE THERAPEUTICS, INC. : JEFFERIES RAISES TARGET PRICE TO $64 FROM $54 - webull.com
Travere Therapeutics, Inc. Stock 12‑Month Price Target Raised to $68.36, Implies 22% Upside - TradingView
Travere Therapeutics to Participate at Upcoming Investor Conferences - marketscreener.com
Travere Therapeutics (NASDAQ:TVTX) Given New $75.00 Price Target at TD Cowen - MarketBeat
TRAVERE THERAPEUTICS, INC. : TD COWEN RAISES TARGET PRICE TO $75 FROM $60 - webull.com
Stifel raises Travere Therapeutics price target on FSGS launch By Investing.com - Investing.com Nigeria
Stifel raises Travere Therapeutics price target on FSGS launch - Investing.com
Travere Therapeutics stock hits 52-week high at 61.76 USD - Investing.com
Travere Therapeutics Rallies After Strong Q2 FILSPARI Growth - Quiver Quantitative
Travere Therapeutics (NASDAQ:TVTX) Sets New 52-Week HighHere's Why - marketbeat.com
Travere Therapeutics stock hits 52-week high at 61.76 USD By Investing.com - Investing.com Nigeria
S&P 500 Futures Up in Premarket Trading; Shopify, Travere Therapeutics Lead - Barron's
Travere Therapeutics Inc (TVTX) (Q2 2026) Earnings Call Highligh - GuruFocus
Travere Therapeutics Inc (TVTX) (Q2 2026) Earnings Call Highlights: Record FILSPARI Demand and ... - Yahoo Finance
Is Travere Therapeutics Inc (TVTX) Positioned for Growth After Q - GuruFocus
Earnings call transcript: Travere Therapeutics jumps on q2 2026 sales beat - Investing.com
Travere Therapeutics Q2 Earnings Call Highlights - MarketBeat
Travere Therapeutics (NASDAQ:TVTX) Issues Quarterly Earnings Results - MarketBeat
Travere (TVTX) Reports Q2 Earnings: What Key Metrics Have to Say - Yahoo Finance
Travere Therapeutics (TVTX) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Travere Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Travere Therapeutics (TVTX) Releases Q2 2026 Earnings: Revenue Growth but Net Loss Narrows - Quiver Quantitative
Travere Therapeutics (NASDAQ: TVTX) grows FILSPARI sales and issues $525M converts - Stock Titan
Travere Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Earnings Flash (TVTX) Travere Therapeutics, Inc. Reports Q2 Revenue $169.6M, vs. FactSet Est of $157.3M - marketscreener.com
Earnings Flash (TVTX) Travere Therapeutics, Inc. Posts Q2 Adjusted Loss $0.10 per Share, vs. FactSet Est of $-0.13 - marketscreener.com
0.52%
0.07%
자본화:
|
볼륨(24시간):